How HCV has changed the approach to mixed cryoglobulinemia

Clinical and Experimental Rheumatology

Volumn 27, Issue 1 SUPPL. 52, 2009, Pages

  Della Rossa, Alessandra ^a   Baldini, Chiara ^a   Tavoni, Antonio ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Hepatitis C virus; Management; Mixed cryoglobulinemia

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CALCINEURIN INHIBITOR; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHILIN B; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBAVIRIN; RITUXIMAB; STEROID; TACROLIMUS; VIRUS RNA;

CANCER CHEMOTHERAPY; COLON CROHN DISEASE; CRYOGLOBULINEMIA; DISEASE SEVERITY; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CIRRHOSIS; LIVER TOXICITY; LYMPHOMA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 70450247048     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. DELLA ROSSA A, FERRI C, BOMBARDIERI S: From essential mixed cryoglobulinemia to virus induced autoimmnunity: ten years of research in mixed cryoglobulinemia. In: SHOENFELD Y (Ed.) The Decade of autoimmunity. Amsterdam. Elsevier Sciences: 235-43, 1999.
2. ANTONELLI A, FERI C, GALEAZZA M et al.: HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26 (Suppl. 48): S39-47.
3. GATTA A, GIANNINI C, LAMPERTICO P et al.: Hepatotropic viruses: new insights in pathogenesis and treatment. Clin Exp Rheumatol 2008; 26 (Suppl. 48): S33-8.
4. THIMME R, NEUMAN-HAFELIN C, BOETTLER T, BLUM HE: Adaptive Immune responses to hepatitis C virus infection: from viral immunobiology to a vaccine. Biol Chem 2008; 389: 457-467
5. TAVONI A, MOSCA M, FERRI C et al.: Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl. 13): S191-S195.
6. MISIANI R, BELLAVITA P, FENILI D et al.: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117: 573-577
7. AGNELLO V, CHUNG RT, KAPLAN LM: Evidence for a role for hepatitis C virus infection in the pathogenesis of type II mixed cryoglobulinemia. New Engl J Med 1992; 327: 1490-1495
8. LEVO Y, GOREVIC PD, KASSAB HJ, ZUCKER-FRANKLIN D, FRANKLIN EC: Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 1977; 296: 1501-1504
9. FERRI C, ZIGNEGO AL, PILERI SA: Cryoglobulins. J Clin Pathol 2002; 55: 4-13.
10. FERRI C, LA CIVITA L, LONGOMBARDO G, ZIGNEGO AL, PASERO G: Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus 1998; 7: 275-279
11. PAGNOUX C, COHEN P, GUILLEVIN L: Vasculitides secondary to infections. Clin Exp Rheumatol 2006; 24 (Suppl. 41): S71-81.
12. FERRI C, GRECO F, LONGOMBARDO G et al.: Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991; 34: 1606-1610
13. FERRI C, GRECO F, LONGOMBARDO G et al.: Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991; 9: 621-624
14. FERRI C, MARZO E, LONGOMBARDO G et al.: Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 1132-6, 1993.
15. MISIANI R, BELLAVITA P, FENILI D et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756 (Pubitemid 24080221)
16. DAMMACCO F, SANSONNO D, HAN JH et al.: Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84: 3336-3343
17. COHEN P, NGUYEN QT, DENY P et al.: Treatment of mixed cryoglobulinemia with recombinant interferon-alpha and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne 1996; 147: 81-86
18. CASATO M, AGNELLO V, PUCILLO LP et al.: Predictors of long term response to high dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-3873
19. MAZZARO C, CARNIELLO GS, COLLE R et al.: Interferon therapy in HCV-positive mixed cryoglobulinemia: viral and host factors contributing to efficacy of therapy. Ital J Gastroenterol Hepatol 1997; 29: 343-350
20. MAZZARO C, PANARELLO G, CARNIELLO S et al.: Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32: 708-715
21. CALLEJA JL, ALBILLOS A, MORENO-OTERO R et al.: Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999; 13: 1179-1186
22. SABRY AA, SOBH MA, SHEAASHAA HA et al.: Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2000; 17: 1924-1930
23. MAZZARO C, ZORAT F, CAIZZI M et al.: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 632-638 (Pubitemid 40501678)
24. CACOUB P, SAADOUN D, LIMAL N, SENE D, LIDOVE 0, PIETTE JC: PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis Cvirus-related systemic vasculitis. Arthritis Rheum 2005; 52: 911-915
25. SAADOUN D, RESCHE-RIGON M, THIBAULT V, PIETTE JC, CACOUB P: Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemiavasculitis: a long-term follow-up study. Arthritis Rheum 2006; 54: 3696-706.
26. LEVINE JW, GOTA C, FESSLER B, CALABRESE L, COOPER SM: Persistent cryoglobulinemic vasculitis following successful treatment of Hepatitis C Virus. J Rheumatol 2005; 32: 1164-1167
27. QUARTUCCIO L, DE MARCHI G, FABRIS M, DE VITA S: Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology (Oxford) 2007; 46: 367-368
28. LA ClVITA L, ZIGNEGO AL, LOMBARDINI F et al.: Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996; 23: 1641-1643 (Pubitemid 26290596)
29. DEUTSCH M, HADZIYANNIS SJ: Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008; 15: 2-11. (Pubitemid 350243574)
30. BEUTHIEN W, MELLINGHOFF HU, KEMPIS J: Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24: 507-515 (Pubitemid 43055044)
31. CID MC, HERNANDEZ-RODRIGUEZ J, ROBERT J et al.: Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenicactivity. Arthritis Rheum 1999; 42: 1051-1055
32. LEVO Y, GOREVIC PD, KASSAB HJ, TOBIAS H, FRANKLIN EC: Liver involvement in the syndrome of mixed cryoglobulinemia. Ann Intern Med 1977; 87: 287-292
33. BOMBARDIERI S, FERRI, DI MUNNO O, PASERO G: Liver involvement in essential mixed cryoglobulinemia. Ric Clin Lab 1979; 9: 361-368
34. ZAJA F, DE VITA S, MAZZARO C et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-3834 (Pubitemid 36857853)
35. DE VITA S, QUARTUCCIO L, FABRIS M: Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007; 39 (Suppl. 1): S122-S128.
36. SAADOUN D, RESCHE-RIGON M, SENE D, PERARD L, KARRAS A, CACOUB P: Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus associated cryoglobulinemic vasculitis. Ann Rheum Dis 2008; 67: 1431-1526
37. NIETERS A, KALLINOWSKY B, BRENNAN P et al.: Hepatitis C and Risk of Lymphoma: Results of the European Multicenter Case-Control Study EPILYMPH. Gastroenterology 2006; 131: 1879-1886
38. FERRI C, LA CIVITA L, LONGOMBARDO G, ZIGNEGO AL, PASERO G: Mixed cryoglobulinemia: a cross road beetwen autoimmune and lymphoproliferative disorder. Lupus 1998; 7: 275-279
39. PATRIARCA F, SILVESTRI F, FANIN R et al.: Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol 2001; 112: 370-372
40. TERMINE O, LEFRERE F, BRONOWICKI JP et al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94. (Pubitemid 34753478)
41. DIZDAR O, TAPAN U, AKSOY S, HARPUTLUOGLU H, KILICKAP S, BARISTA I: Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol 2008; 80: 381-385
42. BESSON C, CANIONI D, LEPAGE E et al.: Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes del'Adulte programs. J Clin Oncol 2006; 24: 953-960
43. VISCO C, ARCAINI L, BRUSAMOLINO E et al.: Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006; 17: 1434-1440
44. POYNARD T, YUEN MF, RATZIU V, LAI CV: Viral hepatitis C. Lancet 2003; 362: 2095-100.
45. KUJAWSKA A, CLEMENTS M, WISE CM, ROBERTS WN: Hepatitis C and methotrexate. Arthritis Rheum 2003; 49: 843-845
46. BOMBARDIERI M, ALESSANDRI C, LABBADIA G et al.: Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6: R137-R141.
47. GIANNITTI C, BELLISAI F, FERRI C, GALEAZZI M: Treatment strategies for a patient with rheumatoid arthritis and hepatitis C. Expert Opin Pharmacother 2009; 10: 579-87.
48. BALDINI C, DELLE SEDIE A, BOMBARDIERI S: From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis a concurrent morbidities who are excluded from clinical trials? Clin Exp Rheumatol 2005; 23: 893-904.
49. MOK MY, NG WL, YUEN MF, WONG RW, LAU CS: Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363-368
50. EVERSON GT: Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8 (Suppl.): S19-S27.
51. BRILLANTI S, VIVARELLI M, DE RUVO N et al.: Slowly tapering off steroids protects graft against hepatitis recurrence after liver transplantation. Liver Transpl 2002; 8: 884.
52. BERENGUER M, CRIPPIN J, GISH R et al.: A model to predict severe HCV related disease following liver transplantation. Hepatology 38: 34, 2003.
53. BELLI LS, ARBERTI AB, VANGELI M et al.: Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003; 9: 201.
54. DESAI SB: Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-790 (Pubitemid 44350122)
55. WASLEY A, ALTER MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liv Dis 2000; 20: 1-16.
56. EVERHART JE, WEY Y, ENG H et al.: Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 2001; 29: 1220-1226
57. DAVIS GL, ALBRIGHT JE, COOK SF, ROSENBERG DM: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338
58. ALTER MJ: Epidemiology of hepatitis C. Hepatology 1997; 26 (Suppl. 1): S62-S65.
59. KIM WR, BROWN RS JR, TERRAULT NA, EL-SERAG H: Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242 (Pubitemid 34700782)
60. LUNA HR, VARGAS H: Management of hepatitis C virus infection in the setting of liver transplantation. Liv Transpl 2005; 11: 479-89.
61. TEIXEIRA R, MENEZES EG, SCHIANO TD: Therapeutic management of recurrent hepatitis C after liver transplantation. Liv Int 2007; 27: 302-312 (Pubitemid 46416619)
62. GURUSAMY KS, OSMANI B, XIROUCHAKIS E, BURROUGHS AK, DAVIDSON BR: Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2009; 21: CDO06803.
63. BAHRA M, NEUMANN UP, JACOB D et al.: MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005; 5: 406.
64. WEISNER RH, SHORR JS, STEFFEN BJ et al.: mycophenolate mofetil combination therapy improves long term outcomes after liver transplantation in patients with or without hepatitis C. Liver Transpl 2005; 11: 750.
65. JAIN A, KASHYAP R, DEMETRIS AJ et al.: A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40.
66. NELSON DR, SOLDEVILA-PICO C, REED A et al.: Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064.
67. KLINTMALM GB, WASHBURN WK, RUDICH SM et al.: Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521-1531
68. MAGY N, CRIBIER B, SCHMITT C et al.: Effects of corticosteroids on HCV infection. Intern J Immunopharmacol 1999; 21: 253-61.
69. HENRY SD, METSELAAR HJ, VAN DIJCK J, TIALNUS HW, VAN DER LAAN UW: Impact of steroids on Hepatitis C virus replication in vivo and in vitro. Ann NJ Acad Sci 2007; 1110: 439-447
70. WIETZKE- BRAUN P, BRAUN F, SATTLER B, RAMADORI G, RINGE B: Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol 2004; 10: 2213-2217
71. BERENGUER M, AGUILERA V, PRIETO M et al.: Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 712-722
72. SANDERS S, HARISDANSKGUL V: Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002; 323: 390-393
73. SAVIKKO J, VON WILLEBRAND E, HÄYRY P: Leflunomide analogue FK 778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003; 76: 455-458
74. HONG-WEI Y, JUN L, Ji QIANG C, SHU-YUN X: Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells. World J Gastroenterol 2004; 10: 1608-1611
75. METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004; 43: 315-320
76. REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001; 10: 480-483 (Pubitemid 32675047)
77. CHAN ATY, BRADLOW A, MCNALLY J: Leflunomide induced vasculitis. A dose response relationship. Rheumatology 2003; 42: 492-493
78. SMOLEN JS, KALDEN JR, SCOTT DL et al.: and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicentre trial. Lancet 1999; 353: 259-266
79. GOTO K, WATASHI K, MURATA T, HISHIKI T, HIJIKATA M, SHIMOTOHNO K: Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Bioch and Biophys Research Comm 2006; 343: 879-884
80. GALEAZZI M, BELLISAI F, GIANNITTI C, MANGANELLI S, MOROZZI G, SEBASTIANI GD: Safey of cyclosporin A in HCV infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 2007; 1110: 544-549
81. ARINSOY T, DERICI U, YUKSEL A, REIS KA, SINDEL S: Cyclosporine-A treatment and a rare complication: Raynaud's phenomenon. Int J Clin Pract 2005; 59: 863-864 (Pubitemid 43904559)
82. STANGL JR, CARROL KL, ILLICHMANN M, STRIKER R: Effect of antimetabolite immunosuppressant on flaviviridae, including hepatitis C virus. Transplantation 2004; 77: 562-567
83. DAINA E, SCHIEPPATI A, REMUZZI G: Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999; 130: 422-426 (Pubitemid 29111224)
84. IACCARINO L, RAMPUDDA M, CANOVA MG, DELLA LIBERA S, SARZI-PUTTINI PC, DORIA A: Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases? Autoimmunity Reviews 2007; 6: 190-195
85. MOSCA M, RUIZ-IRASTORZA G, KHAMASHTA MA, HUGHES GR: Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001; 1: 1065-1075
86. HAUBITZ M: ANCA associated vasculitis: diagnosis, clinical characteristics and treatment. VASA 2007; 36: 81-89
87. LAVANCY D. MC MAHON B: Worldwide prevalence and prevention of hepatitis C. In LIANG TJ, HOOFNAGLE JH (Eds.). Hepatitis C. San Diego. Academic Press 2000: 186-201.
88. NELSON DR, LIM LH, MAROUSIS GC: Activation of tumor necrosis factor alpha system in chronic hepatitis C virus infection. Digestive Disease Sciences 1997; 42: 2487-94.
89. PETERSON JR, HSU FC, SIMKIN PA, WERNER MH: Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C virus infection. Ann Rheum Dis 2003; 62: 1078-1082
90. ZEINN NN and ETANERCEPT STUDY GROUP: Etanercept as an adjuvant to interferon and ribavirin in treatment naïve patients with chronic Hepatitis C virus infection: a phase 2 randomized, double blind placebo controlled study. J Hepatol 2005; 42: 315-322
91. LAMPRECHT P, TILL A, STEIMAN J, ARIES PM, GROSS WL: Current state of biological in the management of systemic vasculitides. Ann N Y Acad Sci 2007; 1110: 26.1-70.
92. ATZENI F, DORIA A, CARRABBA M, TURIEL M, SARZI-PUTTINI P: Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007; 6: 529-536 (Pubitemid 47374618)
93. GOLDBACH MANSKY RT, SOOUTO CARNEIRO MM, MAHADEVAN V et al.: TNF blockade results in an increase of CD20+ CD27+ (memory) B cells in the peripheral circulation of rheumatoid arthritis (RA) patients (abstract) Arthritis Rheum, 2002.
94. IMPERATO AK, BINGHAM CO, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S108-114.
95. ZAJA F, DE VITA S, RUSSO D et al.: Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002; 46: 2252-2254
96. SANSONNO D, DE RE V, LAULETTA G, TUCCI FA, BOIOCCHI M, DAMMACCO F: Monoclonal antibody treatment of mixed cryo-globulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101: 3818-3826
97. ROCCATELLO D, BALDOVINO S, ROSSI D et al.: Long term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061
98. QUARTUCCIO L, SOARDO G, ROMANO G et al.: Rituximab treatment for glomerulonephritis in HCV associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology 2006; 45: 842-846
99. SAADOUN D, ROSENZWAJG M, LANDAU D, PIETTE JC, KLATZMANN D, CACOUB P: Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111: 5334-41.
100. CACOUB P, DELLUC A, SAADOUN D, LANDAU DA, SENE D: Anti CD-20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 63: 283-287
101. PETRARCA A, RIGACCI L, MONTI M et al.: Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liv Dis 2007; 39 (Suppl. 1): S129-S133.